NRAS and ameloblastoma: Mutually exclusive and less common mutations affecting other MAPK-related genes, such as KRAS, NRAS, HRAS, and FGFR2 (a receptor whose stimulation activates MAPK/ERK pathway) have been reported in BRAF wild-type ameloblastomas [51, 52, 54, 55, 58, 62, 72].